Navigation Links
New Data Shows GeNO LLC Nitric Oxide Delivery System Provided Nitric Oxide With Low Levels of Nitrogen Dioxide for Heart Transplant Patient Evaluation
Date:4/19/2012

s for both in-hospital and ambulatory inhaled nitric oxide systems will help address the cost, complexity and lack of portability of current treatment regimens, and potentially reach a much larger group of patients. At present, GeNO's delivery technologies are investigational and are not approved by regulatory authorities.

GeNO recently completed a 10 patient Phase 2 pilot study of NITROSYL as a diagnostic in Pulmonary Arterial Hypertension (PAH) to obtain preliminary safety and feasibility data and is currently performing a dose-escalation trial for the treatment of Pulmonary Hypertension in patients with PAH and Pulmonary Hypertension secondary to Idiopathic Pulmonary Fibrosis (PH-IPF). Additional study details can be found on http://clinicaltrials.gov/ -- ClinicalTrials.gov Identifier NCT01265888. 

ABOUT GENO LLC                                        
GeNO LLC, founded in 2006, is a privately held, advanced development-stage technology company that is developing innovative nitric oxide (NO) generation and delivery platforms to enable the true potential of inhaled nitric oxide to be realized. The company is focused on applying the new technology to deliver inhaled nitric oxide to patients in a wide variety of settings, including ambulatory and in-home use for potential chronic treatment. GeNO's NITROSYL Systems will be regulated by the FDA as new drugs with their own NDAs. These systems have been designated as Combination Products by the FDA Office of Combination Products, with the Division of Cardiovascular and Renal Products designated as the lead reviewer for GeNO's initial INDs.

ABOUT AURORA HEALTH CARE
Aurora Health Care is a not-for-profit Wisconsin based health care prov
'/>"/>

SOURCE GeNO LLC
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. PTC124 Shows Promising Activity in Cystic Fibrosis; Phase 2 Proof-of-Concept Data Published in the Lancet
2. Video: New Survey Shows Three in Four School Nurses Have Students at Risk for Severe Allergic Reactions Who Do Not Bring Auto-Injectable Epinephrine to School
3. Global Study Shows That Majority of Women with Osteoporosis Do Not Consider Themselves at Higher Risk for Fractures
4. Oil palm plantations are no substitute for tropical rainforests, a new study shows
5. New carbon material shows promise of storing large quantities of renewable electrical energy
6. Research Shows How AHCC(R) May Help Fight Flu and Other Infectious Agents
7. Jellyfish Protein Shows Potential to Help With Memory
8. Nycomeds Daxas(R) Shows Encouraging Preliminary Results in Phase III COPD Studies
9. New Research Shows Many Patients with Persistent Cough and Sputum Actually had Airway Obstruction Consistent with COPD
10. Interim Analysis of Top-Line Data From Phase II/III Study Shows Favorable Efficacy & Safety for Cortheras Relaxin in Acute Heart Failure
11. Potentia Pharmaceuticals Drug Candidate for Age-Related Macular Degeneration Shows Positive Safety Profile in Phase I Clinical Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... 2014 Date: Friday, April 11, 2014 ... Warrington Country Club, 1360 Almshouse Road, Warrington, Pa. ... national nonprofit organization solely dedicated to finding a cure ... for those affected worldwide, will host its annual Crystal ... in Warrington, Pa. , Each year, the Crystal ...
(Date:1/14/2014)... New York, NY (PRWEB) January 14, 2014 ... has initiated coverage of Alliqua, Inc. (OTCQB: ALQA). ... manufacturing, and marketing proprietary products to serve the ... http://equitiesiq.com/reports/alliqua/ , In late 2012, Alliqua was ... which launched the company’s new strategy to become ...
(Date:1/14/2014)... Jan. 14, 2014  RXi Pharmaceuticals Corporation ... discovering, developing and commercializing innovative therapies addressing ... today announced that it received the Notice ... and Trademark Office on its unique self-delivering ... fibrosis. The patent covers the use of ...
(Date:1/14/2014)... (PRWEB) January 14, 2014 During the ... is now known as “The Doctor’s Plague.” In this ... to wash their hands. This led, at times, to ... medical interns and hospital staff today don’t know that ... patients. The CBCD explains. , A study showed that ...
Breaking Biology Technology:Hepatitis B Foundation to Host Annual Crystal Ball Gala 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 2RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 3Study: Fatigued Medical Interns Infect Their Patients with Herpes Viruses; The CBCD Sees a Parallel with “The Doctor’s Plague” 2Study: Fatigued Medical Interns Infect Their Patients with Herpes Viruses; The CBCD Sees a Parallel with “The Doctor’s Plague” 3
... 23, 2011 Novavax, Inc. (Nasdaq: NVAX ) ... results in a press release to be issued after 8:00 ... hold an investor conference call at 10:00 a.m. The call ... Dr. Rahul Singhvi and other members of senior management. The ...
... SA , a Swiss-based biotechnology company with technologies for ... stable mammalian cell lines for therapeutic ... sequencing of their proprietary Chinese hamster ovary (CHO) cell ... performed in collaboration with the Institute of Biotechnology ...
... MARLBOROUGH, Mass., March 23, 2011 Advanced Cell Technology, ... a leader in the field of regenerative medicine, announced ... allowed the Company,s patent application to provide broad intellectual ... preparations of retinal pigment epithelial (RPE) cells from human ...
Cached Biology Technology:Selexis SA and the University of Lausanne Announce the Complete Sequencing of the Selexis SURE CHO-M Genome 2Selexis SA and the University of Lausanne Announce the Complete Sequencing of the Selexis SURE CHO-M Genome 3Selexis SA and the University of Lausanne Announce the Complete Sequencing of the Selexis SURE CHO-M Genome 4ACT to Be Issued Broad Patent for Human ES Cell-derived RPE Cells in China 2ACT to Be Issued Broad Patent for Human ES Cell-derived RPE Cells in China 3
(Date:4/15/2014)... Center in Greenbelt, Md., is home to hundreds ... At Goddard, some of the most cutting-edge Earth ... of that cutting-edge innovation has earned a Goddard ... Society for Anthropology and Geography awards the Vega ... has shown excellence in the fields of physical ...
(Date:4/15/2014)... study of nearly 1,000 mother-child pairs, researchers from ... prenatal exposure to selective serotonin reuptake inhibitors (SSRIs), ... other disorders, was associated with autism spectrum disorder ... study, published in the online edition of ... ASD and DD cases, and population-based controls, where ...
(Date:4/15/2014)... University of Missouri researchers have previously shown that a ... exercise exists. In a new study, Frank Booth, a ... found a potential link between the genetic pre-disposition for ... which mental maturation occurs. , For his study, Booth ... activity or extreme laziness. Booth then put the rats ...
Breaking Biology News(10 mins):Goddard scientist receives Vega Medal from King of Sweden 2Study: SSRI use during pregnancy associated with autism and developmental delays in boys 2Genetic pre-disposition toward exercise and mental development may be linked 2
... (Jan. 28, 2009) Virginia Commonwealth University researchers have ... in regulating mitochondria, the energy-producing machines of cells. This ... new treatments for heart disease to boost energy in ... of cancer. In the study, published online Jan. ...
... available in French . MONTREAL, ... to announce that Concordia,s Centre for Structural and Functional ... by nine universities which are part of the Cellulosic ... the conversion of agricultural waste into biofuel is being ...
... This release is available in German . ... year as a result of pneumococcal infection, which causes ... and the elderly are especially at risk. Vaccines are ... and increasing resistance to antibiotics is making treatment more ...
Cached Biology News:Deceiving cell walls 2
... analysis kit for 10 chips provides the ... analysis with the Experion automated electrophoresis system. ... 3 x 520 microliters Pro260 gel, 45 ... (10-260 kD), 400 microliters Pro260 sample buffer, ...
... original Gene Pulser apparatus and accessory modules the ... in the Gene Pulser II system, which features ... Gene Pulser II system has the dual advantages ... range of settings to target specific cell types ...
Experion Pro260 chips are the microfluidic chips used to perform protein analysis with the Experion automated electrophoresis system. Each chip has the capacity to run 10 protein samples. Supplied as...
... Pro260 reagents and supplies, for 10 ... sufficient to perform protein analysis with ... electrophoresis system. Supplied are 3 x ... Pro260 stain, 60 microliters Pro260 ladder ...
Biology Products: